Didi Global Expected to Price IPO at Top of Range of $13 to $14/Share or Above
-Reuters
https://www.reuters.com/business/didi-flags-ipo-share-price-top-range-or-above-source-2021-06-29/
IPO Preview: 12 Deals To Watch This Week
This week’s IPO schedule could include dozens of companies going public including several high-profile names. Here is a look at some of the top planned offerings of the week that investors should watch.
Daniel Loeb-Backed SentinelOne Prices Upsized US IPO At $8.1B Valuation: Reuters
Billionaire investor Daniel Loeb’s hedge fund, Third Point-backed cybersecurity firm SentinelOne Inc (NYSE:S), aims to raise $1.02 billion from the…
One In Five Russell 3000 Additions Went Public Via SPAC: What Investors Should Know
One of the biggest events for investors last week was the new additions to the Russell 3000 Index. The inclusion in the index means several ETFs have to add shares of the stocks as part of the rebalancing efforts.
DFP Healthcare Acquisitions Corp. Announces Proposed Business Combination With The Oncology Institute; Transaction Values Combined Co. At Pro Forma Enterprise Value Of $842M
The Oncology Institute is the U.S. Market Leader in Value-Based Oncology Care
DFP Healthcare Acquisitions Corp ("DFP") (NASDAQ:DFPH, DFPHW)))), a special purpose acquisition company sponsored by an affiliate
This Week’s Scheduled IPOs
With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are scheduled to trade publicly this week.
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment.
Toyota Backed Driverless Startup Pony.ai Aims US Listing: Reuters
Toyota Motor Corp (NYSE:TM) backed autonomous driving tech company, Pony.ai, is eyeing U.S. listing plans to fund its goal…
Sickle Cell Biotech, Graphite Bio Prices Upsized Initial Public Offering
Graphite Bio Inc (NASDAQ:GRPH) is set to go public on the heels of a $238 million raise less than ten months…
Alzheimer’s Biotech Acumen Pharmaceuticals Prices $125M IPO Soon After Biogen’s Aduhelm Approval
Acumen Pharmaceuticals Inc has set the terms for its IPO to raise around $125 million to take ACU193, an antibody against amyloid-beta oligomers, to the end of phase 2 in Alzheimer’s disease.